20/20 BioLabs Integrates Advanced CKD Prediction Technology into Longevity Test Program through Exclusive U.S. License Agreement with ROKIT Healthcare

20/20 BioLabs has partnered with ROKIT Healthcare to integrate a CKD prediction algorithm into its Longevity Test Program. The agreement aims to enhance response to 3-D bio-printed therapies by predicting systemic inflammation, measured by biomarkers such as CRP. The partnership expands 20/20's suite of biomarker-based disease-risk assessment tools, providing earlier insights and more personalized risk trajectories for chronic kidney disease.